ARWR
Arrowhead Pharmaceuticals Inc
68.80$
+3.5%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.7% | 77.8% | 70.6% | 65.3% | 70.6% | 75.8% | 61.7% | 54.2% | 58.6% | 54.8% | 61.0% | 68.6% | |
| 72.5% | 61.4% | 66.6% | 23.9% | 27.0% | 63.4% | 27.5% | 26.0% | 15.6% | 14.5% | 9.0% | 16.4% | |
| 84.3% | 74.7% | 66.6% | 63.1% | 68.6% | 73.9% | 60.4% | 51.8% | 54.4% | 52.7% | 59.7% | 66.4% | |
| 0.0% | 0.1% | 0.1% | 0.1% | 0.3% | 0.2% | 0.2% | 1.4% | 0.2% | 0.0% | 0.0% | 0.5% | |
| 0.0% | 0.0% | 1.0% | 0.8% | 1.1% | 0.9% | 0.8% | 0.6% | -3.1% | – | – | – | |
| 2.1% | 3.4% | 12.0% | 14.9% | 12.5% | 6.6% | 5.9% | 6.9% | 15.9% | 43.8% | – | – | |
| 0.6% | 18.8% | 17.3% | 19.7% | 16.8% | 4.9% | 2.9% | – | – | – | – | – | |
| 0.6% | 18.8% | 17.3% | 19.7% | 16.8% | 4.9% | 2.9% | 1.9% | 1.7% | 1.3% | 0.8% | 0.5% | |
| 9.2% | 17.1% | 25.9% | 22.3% | 14.7% | 30.2% | 11.6% | 42.4% | 39.5% | 62.5% | 83.2% | 63.7% | |
| 6.5% | 12.0% | 20.0% | 18.0% | 11.1% | 27.7% | 7.8% | 20.6% | 20.1% | 13.8% | 9.1% | 14.1% | |
| 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | 3.3% | 0.2% | 0.3% | 0.4% | 1.4% | 0.6% | 3.4% | |
| 1.4% | 3.8% | 9.5% | 3.9% | 2.5% | 2.2% | 1.3% | 1.3% | 0.4% | 4.7% | 1.0% | 1.3% | |
| 0.4% | 0.4% | 2.0% | 2.2% | 1.9% | – | – | – | – | – | 34.5% | 15.5% | |
| 91.1% | 83.3% | 74.6% | 78.3% | 85.8% | 69.9% | 88.4% | 57.6% | 57.6% | 35.4% | 16.3% | 33.6% | |
| -122.9% | -239.4% | -310.8% | -416.1% | -436.6% | -119.9% | -96.4% | -90.8% | -118.6% | -134.0% | -142.6% | -117.5% | |
| 25.7% | 43.4% | 47.6% | 71.0% | 74.9% | 28.2% | 19.3% | 14.6% | 15.2% | 13.9% | 10.5% | 9.7% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.